Single User
£3750
PDF
50 pages

Mild Cognitive Impairment Forecast in 14 Major Markets 2017-2027


Mild cognitive impairment (MCI) is a condition in which a person has problems with memory, language, executive function and visuospatial skills that are noticeable to others and can be observed in neuropsychological tests, but are not severe enough to interfere with everyday activities. MCI can further develop into dementia, retain its status, or sometimes revert to the normal cognitive status. A significant proportion of people with MCI later develop Alzheimer’s disease (AD).

This report provides the current prevalent population for Crohn’s disease across 14 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, the two types of MCI (amnestic and non-amnestic), as well as ApoE genotypes in MCI patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global MCI market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of MCI and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific ApoE genotypes on MCI prevalent population.
  • Identify sub-populations within MCI which require treatment.
  • Gain an understanding of the specific markets that have the largest number of MCI patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR MILD COGNITIVE IMPAIRMENT
  • FEATURES OF MILD COGNITIVE IMPAIRMENT PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN ANALYSIS PUBLICATIONS
  • BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES
  • PATIENT-BASED OFFERING
  • ONLINE PRICING DATA & PLATFORMS
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of mild cognitive impairment, total (000s)
  • Table 2. Prevalence of mild cognitive impairment, males (000s)
  • Table 3. Prevalence of mild cognitive impairment, females (000s)
  • Table 4. Patients with Amnestic MCI by Sex (000s)
  • Table 5. Patients with Non-amnestic MCI by Sex (000s)
  • Table 6. MCI Patients with ApoE ε3ε4 or ε4ε4 genotype, total (000s)
  • Table 7. MCI Patients with ApoE ε2ε2 or ε2ε3 genotype, total (000s)
  • Table 8. MCI Patients with ApoE ε3ε3 genotype, total (000s)
  • Table 9. Abbreviations and Acronyms used in the report
  • Table 10. USA Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 11. USA Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 12. Canada Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 13. Canada Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 14. France Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 15. France Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 16. Germany Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 17. Germany Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 18. Italy Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 19. Italy Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 20. Spain Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 21. Spain Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 22. UK Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 23. UK Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 24. Russia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 25. Russia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 26. Japan Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 27. Japan Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 28. China Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 29. China Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 30. India Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 31. India Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 32. Australia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 33. Australia Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 34. Brazil Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 35. Brazil Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
  • Table 36. Mexico Prevalence of Mild Cognitive Impairment by 5-yr age cohort, males (000s)
  • Table 37. Mexico Prevalence of Mild Cognitive Impairment by 5-yr age cohort, females (000s)
Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Spain, United Kingdom, United States of America